#1 Clinical Trials Search in Europe

Tamuzimod Acetate

This article discusses the ongoing clinical trials of Tamuzimod Acetate, also known as VTX002, for the treatment of moderate to severe ulcerative colitis. Tamuzimod Acetate is a selective immunosuppressive agent being studied in a Phase 2 multicenter, randomized, double-blind, placebo-controlled trial. The study aims to evaluate the efficacy and safety of this new drug in patients who have not responded well to conventional or biologic therapies.

Table of Contents

What is Tamuzimod?

Tamuzimod acetate, also known as VTX002 or OPL-002, is a new medication being studied for the treatment of moderately to severely active ulcerative colitis[1]. Ulcerative colitis is a chronic inflammatory bowel disease that affects the large intestine, causing symptoms such as diarrhea, abdominal pain, and rectal bleeding.

How Does Tamuzimod Work?

Tamuzimod belongs to a class of drugs called selective immunosuppressive agents[1]. These medications work by modulating the immune system to reduce inflammation in the body. In the case of ulcerative colitis, this can help alleviate symptoms and promote healing of the intestinal lining.

Treating Ulcerative Colitis with Tamuzimod

Tamuzimod is being developed as a potential new treatment option for patients with ulcerative colitis who have not responded well to other therapies. It may be particularly helpful for those who have experienced:

  • Inadequate response to conventional therapies like corticosteroids or 5-aminosalicylic acid (5-ASA) compounds
  • Loss of response to biologic therapies such as anti-TNF alpha antibodies, anti-interleukin drugs, or anti-integrin antibodies
  • Intolerance to other medications used for ulcerative colitis
This new drug aims to provide an alternative for patients who have limited treatment options[1].

Current Clinical Trial

Tamuzimod is currently being evaluated in a Phase 2 clinical trial[1]. This study aims to assess:

  1. The efficacy of tamuzimod in inducing clinical remission after 13 weeks of treatment
  2. Improvements in endoscopic appearance of the colon
  3. Symptomatic response and remission
  4. Changes in histology (microscopic examination of colon tissue)
  5. Mucosal healing
The trial is also evaluating the safety, tolerability, and pharmacokinetics (how the drug moves through the body) of tamuzimod[1].

Dosage and Administration

Tamuzimod is being studied as an oral medication in the form of film-coated tablets[1]. The exact dosage is still being determined through clinical trials, but the maximum daily dose being studied is 60 mg[1]. The treatment period in the current trial is up to 36 weeks[1].

Potential Side Effects

As tamuzimod is still in clinical trials, the full range of potential side effects is not yet known. However, as with all immunosuppressive medications, there may be an increased risk of infections. The ongoing clinical trial is carefully monitoring participants for any adverse effects[1].

Conclusion

Tamuzimod acetate represents a promising new approach to treating moderate to severe ulcerative colitis. While still in the investigational stage, it offers hope for patients who have not found relief with existing treatments. As research continues, we will learn more about the effectiveness and safety of this medication in managing ulcerative colitis[1].

Aspect Details
Drug Name Tamuzimod Acetate (VTX002)
Trial Phase Phase 2
Condition Moderate to Severe Ulcerative Colitis
Primary Endpoint Clinical remission at Week 13
Key Secondary Endpoints Endoscopic improvement, symptomatic remission, histologic remission
Administration Oral film-coated tablet
Maximum Daily Dose 60 mg
Treatment Duration 13 weeks (initial assessment)
Key Inclusion Criteria Adults 18-80 years, UC diagnosis ≥3 months, inadequate response to prior therapies
Key Exclusion Criteria Severe extensive colitis, active infections, recent cancer history

FAQ

  • What is Tamuzimod Acetate? Tamuzimod Acetate, also known as VTX002, is a selective immunosuppressive agent being studied as a potential treatment for moderate to severe ulcerative colitis. It is administered as a film-coated tablet for oral use.
  • What is the main goal of the clinical trial? The main goal of the clinical trial is to assess the efficacy of Tamuzimod Acetate in achieving clinical remission after 13 weeks of treatment in patients with moderately to severely active ulcerative colitis.
  • Who can participate in this clinical trial? Participants must be 18 to 80 years old (18 to 75 in Germany and Italy), diagnosed with ulcerative colitis for at least 3 months, and have moderately to severely active disease. They must have shown inadequate response, loss of response, or intolerance to at least one conventional or biologic therapy.
  • What are some of the exclusion criteria for the trial? Some exclusion criteria include severe extensive colitis, diagnosis of Crohn's disease, active infections, history of cancer within the last 5 years, and certain cardiovascular conditions. Pregnant or breastfeeding women are also excluded.
  • What are the secondary objectives of the study? Secondary objectives include assessing the drug's effect on endoscopic improvement, symptomatic remission, histologic remission, mucosal healing, as well as evaluating its safety, tolerability, and pharmacokinetics.

Ongoing Clinical Trials on Tamuzimod Acetate

  • Study on the Effects of Tamuzimod in Patients with Moderate to Severe Ulcerative Colitis

    Not recruiting

    2 1
    Investigated drugs:
    Bulgaria Czechia Germany Hungary Italy Lithuania +2

Glossary

  • Ulcerative Colitis: A chronic inflammatory bowel disease that affects the lining of the large intestine (colon) and rectum, causing inflammation and ulcers.
  • Clinical Remission: A state where the signs and symptoms of the disease are significantly reduced or absent, as measured by specific clinical scores.
  • Endoscopic Improvement: A reduction in visible inflammation and ulceration of the colon lining when viewed through an endoscope.
  • Histologic Remission: The absence of microscopic inflammation in tissue samples taken from the colon.
  • Mucosal Healing: The restoration of the intestinal lining to a normal, healthy state, which is associated with better long-term outcomes in ulcerative colitis.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Modified Mayo Score (MMS): A scoring system used to assess the severity of ulcerative colitis, considering factors such as stool frequency, rectal bleeding, and endoscopic findings.
  • Immunosuppressive Agent: A medication that reduces the activity of the immune system, often used to treat autoimmune diseases like ulcerative colitis.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-tamuzimod-in-patients-with-moderate-to-severe-ulcerative-colitis/